leuprolide (lupron) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. It acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. Leuprolide acetate used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, uterine leiomyomata (fibroids), endometriosis and precocious puberty.   NCATS

Chemistry

  • SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6
  • InChIKey: GFIJNRVAKGFPGQ-LIJARHBVSA-N
  • Mol. Mass: 1209.42
  • ALogP: Missing data
  • ChEMBL Molecules:
    leuprolide  
    leuprolide acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Combination drugs

( leuprolide (lupron), norethindrone )

Alternative names

abbott-43818 | carcinil | (d-leu(6),des-gly-nh2(10),pro-ethylamide(9))-gonadotropin-releasing hormone | eligard | leupline | leuporelin | leuprolide | leuprolide acetate | leuprolide mesylate | leuprorelin | leuprorelina | leuprorelin acetate | leuproreline | leuprorelinum | lo2a | l-pyroglutamyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-leucyl-l-leucyl-l-arginyl-l-proline ethylamide | lucrine | luprolide acetate gel depot | lupron | lupron depot | lupron depot ped | lupron depot-ped | pglu-his-trp-ser-tyr-d-leu-leu-arg-pro-nhc2h5 | pglu-his-trp-ser-tyr-d-leu-leu-arg-pro-nhet | tap-144 | viadur

Organizations (285)

Research & Development (280)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (93)

Approved Indications (3)


 

Endometriosis (approved 1995)

Leiomyoma (approved 1995)

Prostatic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (93)


 

Abortion, Spontaneous (Phase 4)

Acanthosis Nigricans (Phase 2)

Aging (Phase 3)

Alzheimer Disease (Phase 2)

Amenorrhea (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Androgens (Phase 2)

Breast Neoplasms (Phase 3)

Breast Neoplasms, Male (Phase 3)

Bulbo-Spinal Atrophy, X-Linked (Phase 2)

Bulimia Nervosa (Phase 2)

Cardiovascular Diseases (Phase 4)

Castration (Phase 3)

Central Nervous System Diseases (Phase 3)

Cognitive Dysfunction (Phase 2)

Conjunctivitis (Phase 2)

Contraception (Phase 4)

Depression (Phase 2)

Depression, Postpartum (Phase 2)

Drugs, Investigational (Phase 3)

Dysmenorrhea (Phase 3)

Dyspareunia (Phase 3)

Endometriosis (Phase 4)

Fertility (Phase 4)

Fertility Preservation (Phase 3)

Fertilization in Vitro (Phase 4)

Gonadotropin-Releasing Hormone (Phase 3)

Growth and Development (Phase 3)

Healthy Volunteers (Phase 1)

HIV (Phase 1)

Hodgkin Disease (Phase 2)

Hormones (Phase 3)

Hot Flashes (Phase 2/Phase 3)

Hyperandrogenism (Phase 2)

Hypertension (Early Phase 1)

Hypogonadism (Phase 2)

Infertility (Phase 4)

Infertility, Female (Phase 3)

Infertility, Male (Phase 3)

Inflammatory Breast Neoplasms (Phase 2/Phase 3)

Insulin Resistance (Phase 2)

Intestinal Neoplasms (Phase 3)

Leiomyoma (Phase 4)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leuprolide (Phase 3)

Liver Neoplasms (Phase 2)

Lung Diseases (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Luteinizing Hormone (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Menopause (Phase 4)

Multiple Myeloma (Phase 2)

Muscular Atrophy, Spinal (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Obesity (Phase 3)

Obesity, Morbid (Phase 2)

Osteoporosis (Phase 3)

Ovarian Diseases (Phase 4)

Ovarian Hyperstimulation Syndrome (Phase 4)

Ovulation Induction (Phase 4)

Ovum (Phase 4)

Pediatrics (Phase 3)

Pedophilia (Phase 3)

Pelvic Pain (Phase 3)

Pelvis (Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Postmenopause (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Pregnancy (Phase 4)

Pregnancy Complications (Phase 3)

Primary Ovarian Insufficiency (Phase 2)

Prostatic Neoplasms ()

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Puberty (Phase 4)

Puberty, Delayed (Early Phase 1)

Puberty, Precocious (Phase 4)

Quality of Life (Phase 4)

Reproductive Health (Phase 4)

Sclerosis (Phase 3)

Sexual Dysfunction, Physiological (Phase 3)

Sleep Apnea, Obstructive (Phase 4)

Systemic Vasculitis (Phase 3)

Transgender Persons (Phase 1)

Urination Disorders (Phase 3)

Uterine Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 334
  • # of Trial Organizations: 280

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue